ConductScience.org, home

Paper41376258

SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.

Tunheim G and 11 others. APMIS, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway. Papers, record 41376258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41376258

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.
PubMed
Journal
APMIS
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-12-14
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tunheim GGrohttps://orcid.org/0000-0002-8280-8243
2Baranowska-Hustad MMarta
3Lund-Johansen FFridtjof
4Fossum EEvenhttps://orcid.org/0000-0001-7064-0327
5Bhandari SSabin
6Kukule LLiva
7Møller TKRThea Kristine Rogne
8Vikse ELElisabeth L
9Bekkevold TTerese
10Oftung FFredrik
11Robertson AHAnna Haymanhttps://orcid.org/0000-0001-6295-0528
12Næss LMLisbeth M

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
SARS-CoV-2Major topic
Antibodies, ViralMajor topic
Antibody FormationMajor topic
Humans
Male
Female
Middle Aged
Immunoglobulin G
Viral Load
Adult
Antibodies, Neutralizing
Norway
Aged
Spike Glycoprotein, Coronavirus
Longitudinal Studies
Angiotensin-Converting Enzyme 2

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135086614Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022.Euro Surveill2022https://conductscience.org/library/papers/35086614PubMed
235135773
Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London.
BMJ Open2022https://conductscience.org/library/papers/35135773PubMed
332871063Humoral Immune Response to SARS-CoV-2 in Iceland.N Engl J Med2020https://conductscience.org/library/papers/32871063PubMed
434634066Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021.PLoS One2021https://conductscience.org/library/papers/34634066PubMed
532766833SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence.J Infect Dis2020https://conductscience.org/library/papers/32766833PubMed
635278794Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection.Diagn Microbiol Infect Dis2022https://conductscience.org/library/papers/35278794PubMed
734398806Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.Immunohorizons2021https://conductscience.org/library/papers/34398806PubMed
833658326Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.Science2021https://conductscience.org/library/papers/33658326PubMed
937273461Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.Influenza Other Respir Viruses2023https://conductscience.org/library/papers/37273461PubMed
1036585405Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.NPJ Vaccines2022https://conductscience.org/library/papers/36585405PubMed
1137053201The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis.PLoS One2023https://conductscience.org/library/papers/37053201PubMed
1233723411Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.Nature2021https://conductscience.org/library/papers/33723411PubMed
1333890566Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.Euro Surveill2021https://conductscience.org/library/papers/33890566PubMed
1436530491Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom.Lancet Reg Health Eur2023https://conductscience.org/library/papers/36530491PubMed
1538111750Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.Open Forum Infect Dis2023https://conductscience.org/library/papers/38111750PubMed
1637759666From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World.Biology (Basel)2023https://conductscience.org/library/papers/37759666PubMed
1734418980Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.BMC Infect Dis2021https://conductscience.org/library/papers/34418980PubMed
1833684923Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.Nature2021https://conductscience.org/library/papers/33684923PubMed
1933413461Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients.J Transl Med2021https://conductscience.org/library/papers/33413461PubMed
2035611346A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease.Open Forum Infect Dis2022https://conductscience.org/library/papers/35611346PubMed

See all 35 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
41376258SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.APMIS2025https://conductscience.org/library/papers/41376258

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ACE259272PubTator's text mininghttps://conductscience.org/library/genes/59272

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41376258

GET https://conductscience.org/api/papers/v1/41376258/references?page=2